1. The Safety and Efficacy of Full vs
The Safety and Efficacy of Full vs. Reduced Dose Betrixaban in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) Trial

2. Background

3. Methods

4. Study Endpoints and Analysis Cohorts

5. Results: Baseline Characteristics

6. Geometric Mean Betrixaban Concentrations at 10-30 Hours Postdose by Patient Populations

7. Primary EP by Local D-dimer and Dosing Criteria

8. Probability of Symptomatic Events in the Full Dose (80 mg) Betrixaban Group vs. Enoxaparin in Cohort 1

9. Rate of Symptomatic Efficacy Events and Major Bleeding Events Across Cohorts

10. Subgroup Analysis of Primary Efficacy Outcomes in the Full Dose (80mg) Betrixaban vs. Enoxaparin in Overall Efficacy Population

11. Subgroup Analysis of Primary Efficacy Outcomes in the Full Dose (80mg) Betrixaban vs. Enoxaparin in Overall Efficacy Population

12. Conclusions